Patents by Inventor Chien-Yu FANG
Chien-Yu FANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10704051Abstract: The present invention provides an expression element and an expression cassette to establish a novel vector therefrom. The expression element of the present invention has an effect of enhancing the expression level of the target gene so that is highly industrial valuable. Accordingly, the present vector is taken as a novel tool for genetic engineering.Type: GrantFiled: December 29, 2014Date of Patent: July 7, 2020Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Zeng-Weng Chen, Chien-Yu Fang, Hao-Zhen Zeng, Jian-Fong Lai, Weng-Zeng Huang, Shih-Ling Hsuan
-
Patent number: 10208093Abstract: The present invention provides a plasmid, method and kit for producing heat labile enterotoxin B-subunit based on a Bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin B-subunit in the application of vaccine adjuvant.Type: GrantFiled: December 16, 2013Date of Patent: February 19, 2019Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Chien-Yu Fang, Zeng-Weng Chen, Ming-Wei Hsieh, Hao-Zhen Zeng, Jian-Fong Lai, Weng-Zeng Huang, Tzu-Ting Peng
-
Patent number: 10059749Abstract: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.Type: GrantFiled: March 14, 2018Date of Patent: August 28, 2018Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Zeng-Weng Chen, Chien-Yu Fang, Ming-Wei Hsieh, Ping-Cheng Yang
-
Publication number: 20180216119Abstract: The present invention provides an expression element and an expression cassette to establish a novel vector therefrom. The expression element of the present invention has an effect of enhancing the expression level of the target gene so that is highly industrial valuable. Accordingly, the present vector is taken as a novel tool for genetic engineering.Type: ApplicationFiled: December 29, 2014Publication date: August 2, 2018Applicant: Agricultural Technology Research InstituteInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Zeng-Weng CHEN, Chien-Yu FANG, Hao-Zhen ZENG, Jian-Fong LAI, Weng-Zeng HUANG, Shih-Ling HSUAN
-
Publication number: 20180208629Abstract: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.Type: ApplicationFiled: March 14, 2018Publication date: July 26, 2018Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: JIUNN-HORNG LIN, JYH-PERNG WANG, ZENG-WENG CHEN, CHIEN-YU FANG, MING-WEI HSIEH, PING-CHENG YANG
-
Patent number: 9951109Abstract: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.Type: GrantFiled: November 21, 2013Date of Patent: April 24, 2018Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Zeng-Weng Chen, Chien-Yu Fang, Ming-Wei Hsieh, Ping-Cheng Yang
-
Patent number: 9775893Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: October 3, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9757441Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: September 12, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9750790Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: December 19, 2016Date of Patent: September 5, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9750791Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: September 5, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9750792Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: September 5, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9730990Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: August 15, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Publication number: 20170202942Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: March 8, 2017Publication date: July 20, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170196959Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: March 8, 2017Publication date: July 13, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170182142Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better to immune effects.Type: ApplicationFiled: March 8, 2017Publication date: June 29, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170182143Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: March 8, 2017Publication date: June 29, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170182144Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: March 8, 2017Publication date: June 29, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Publication number: 20170151318Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: ApplicationFiled: December 19, 2016Publication date: June 1, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
-
Patent number: 9561267Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: February 5, 2013Date of Patent: February 7, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Publication number: 20170002045Abstract: The present invention provides a plasmid, method and kit for producing heat labile enterotoxin B-subunit based on a Bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin B-subunit in the application of vaccine adjuvant.Type: ApplicationFiled: December 16, 2013Publication date: January 5, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Chien-Yu Fang, Zeng-Weng Chen, Ming-Wei Hsieh, Hao-Zhen Zeng, Jian-Fong Lai, Weng-Zeng Huang, Tzu-Ting Peng